Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.03.31.21254674: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the institutional review boards of all participating medical centers and by the Weizmann Institute of Science.
Consent: All research participants provided written informed consent prior to enrollment.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Study Design: Pregnant women admitted for delivery at eight medical centers in Israel (Hadassah Mt. Scopus, Wolfson Table 2: Resources
Antibodies Sentences Resources Quantification of Anti-COVID-19 Antibodies: Serum samples were thawed, heat-inactivated at 56°C for 30 minutes, and transferred to bar-coded 96-well plates for analysis. Anti-CO…SciScore for 10.1101/2021.03.31.21254674: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: The study was approved by the institutional review boards of all participating medical centers and by the Weizmann Institute of Science.
Consent: All research participants provided written informed consent prior to enrollment.Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable Study Design: Pregnant women admitted for delivery at eight medical centers in Israel (Hadassah Mt. Scopus, Wolfson Table 2: Resources
Antibodies Sentences Resources Quantification of Anti-COVID-19 Antibodies: Serum samples were thawed, heat-inactivated at 56°C for 30 minutes, and transferred to bar-coded 96-well plates for analysis. Anti-COVID-19suggested: NoneIgG and IgM antibody (S1, S2, RBD, N) concentrations were log10-transformed for analyses. IgMsuggested: NoneS1suggested: NoneSoftware and Algorithms Sentences Resources Statistical Analyses: Statistical analyses were performed using Statistix 8 software (Analytical Software, Tallahassee, FL USA) and Prism 5.01 (GraphPad Software; San-Diego, CA, USA). GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Strengths and Limitations: The present study has several strengths and limitations. Its strengths include its multicenter design and patient accrual; our relatively large cohort size; and our diverse patient population. Its limitations include the bias in sample collection as most of the study recruitment occurred during the day, and therefore does not includes most of the emergency cases. However, the method of sample collection did not differ between the study groups and Medical Centers, thus minimizing the impact of this effect on our results. Second, since sample collection began long before the COVID-19 immunization campaign, the duration of sample collection differed somewhat between the groups, with an extended recruitment period for COVID-19 recovered cases. We found no differences in background or demographic parameters among the groups. Third, a history of COVID-19 infection during pregnancy was made by positive RT-PCR results during pregnancy with self-reporting of the time of PCR test. Stricter and more accurate symptom monitoring and repeated sampling during pregnancy may provide a higher resolution delineation of how the immune response develops and transfers, following COVID-19 infection. Fourth, patients presenting with RT-PCR positive within one week prior to delivery were excluded from this study due to safety concerns. Thus, future studies are needed in order to characterize the maternal humoral response to COVID-19 within days of infection.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
